“…Apparently, the residual activity or the dosage in which NR5A1 is expressed will influence the expression of a wide range of proteins in different forms, leading to each of those phenotypes. Another feasible reason that could explain several different clinical features is the oligogenic inheritance for NR5A1 cases, which was already discussed in the literature (Camats, Fernández‐Cancio, Audí, Schaller, & Flück, ; Mazen et al, ) and endorses the idea of the existence of genetic modifiers influencing phenotypic severity, since the same mutation can be associated with different phenotypes. There are some classic examples for that: the already mentioned p.Arg92Trp mutation whose heterozygosis was described associated with different phenotypes such as SRY ‐negative 46,XX OTDS and TDSD and SRY ‐positive 46,XY PGD, including a boy with SRY ‐negative 46,XX OTDS and a girl with SRY ‐positive 46,XY PGD who were siblings (Baetens et al, ; Bashamboo et al, ; Igarashi et al, ; Wang et al, ); the also mentioned p.Asp293Asn mutation whose homozygosis was reported in cases with PGD, CGD, and POI, whereas heterozygous carriers were normal or have PGD in the same family (Lourenço et al, ; Soardi et al, ); and the p.Arg313His associated with POI and PGD (Janse et al, ; Saraco et al, ; Wang et al, ).…”